Clinical trials: Relapsed Small Cell Lung Cancer, open to volunteers
Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autologous potency enhanced anti-DLL3 CAR T cell therapy, in participants…
- Conditions
- Small Cell Lung Cancer (SCLC ), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Gastroenteropancreatic NEC (GEP NEC), Neuroendocrine Prostate Cancer (NEPC)
- Trial name
- NCT07488923
- Testing
- ML261
- Where
- 7 sites in United States
- Volunteers
- 110 people
- Sponsor
- Moonlight Bio, Inc
Small-cell Lung Cancer
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
- Trial name
- NCT07189455
- Testing
- ZG006, Topotecan
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Relapsed Small Cell Lung Cancer
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of Lurbinectedin monotherapy or Lurbinectedin + Irinotecan combined…
- Trial name
- NCT06496048
- Testing
- Lurbinectedin, Irinotecan, Topotecan
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Luye Pharma Group Ltd.
Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
This is a single center, phase Ib/II study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will…
- Trial name
- FLINN (NCT07355205)
- Testing
- Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Washington University School of Medicine
Extensive Disease Small Cell Lung Cancer
A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)
The integration of tarlatamab, a bispecific T-cell engager molecule targeting both DLL3 and CD3, into the treatment algorithm for SCLC will substantially improve the prognosis of patients.
- Trial name
- REPLAT (NCT07699237)
- Testing
- Tarlatamab, Carboplatin, Etoposid
- Volunteers
- 54 people
- Sponsor
- University of Cologne
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
The goal of this clinical trial is to learn if a combination of atezolizumab and standard chemotherapy works to treat sensitive Extensive-stage Small Cell Lung Cancer, progressing after first-line of treatment.
- Trial name
- CARRY-ON (NCT06663098)
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- 25 sites in Italy
- Volunteers
- 142 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Non-small-cell Lung Cancer Patients
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
This is a randomized, non-comparative, phase II study investigating whether: 1) the addition of durvalumab to investigator's choice second line chemotherapy prolongs survival versus investigator's choice second line chemotherapy…
- Trial name
- NCT05568212
- Testing
- Durvalumab, Olaparib tablet, Single-agent chemotherapy
- Where
- Italy
- Volunteers
- 176 people
- Sponsor
- Fondazione Ricerca Traslazionale
Small Cell Lung Cancer Recurrent
Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
This study is a single arm, multi-center, prospective clinical trial. The purpose of this study is to evaluate the efficacy and safety of liposomal irinotecan combined with anlotinib hydrochloride for relapsed small-cell lung…
- Trial name
- NCT06258642
- Testing
- Irinotecan Liposome, Anlotinib
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Fudan University
Small Cell Lung Cancer
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).
- Trial name
- IDeate-Lung02 (NCT06203210)
- Testing
- Ifinatamab deruxtecan, Topotecan, Amrubicin
- Where
- 229 sites in United States, Australia and 21 more
- Volunteers
- 540 people
- Sponsor
- Daiichi Sankyo
Melanoma (Skin), Non Small Cell Lung Cancer
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human…
- Conditions
- Melanoma (Skin), Non Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT06956690
- Testing
- ENV-501
- Where
- 7 sites in United States, Australia
- Volunteers
- 180 people
- Sponsor
- Hummingbird Bioscience
Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC
This is a prospective, single-arm, investigator-initiated clinical study (IIT) designed to evaluate the efficacy and safety of nab-paclitaxel combined with local radiotherapy for patients with extensive-stage small cell lung…
- Trial name
- NCT07547332
- Testing
- Albumin-bound Paclitaxel Combined with Local Therapy, Albumin-Bound Paclitaxel /nab-Paclitaxel
- Volunteers
- 84 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Small Cell Lung Cancer
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).
- Trial name
- NCT06922539
- Testing
- Fenretinide
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- SciTech Development, Inc.
Small Cell Lung Cancer
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain.
- Trial name
- NCT07365241
- Testing
- ABBV-706, Topotecan, Lurbinectedin
- Where
- 72 sites in United States, Austria and 8 more
- Volunteers
- 531 people
- Sponsor
- AbbVie
Small Cell Lung Cancer
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
This study is a prospective, multicenter, single arm Phase II exploratory study. It is expected to include 24 first-line patients with small cell lung cancer who have progressed after 6 months of treatment with platinum…
- Trial name
- NCT06467786
- Testing
- Irinotecan hydrochloride liposome injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tang-Du Hospital
Relapsed Malignant Solid Neoplasm
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
- Trial name
- NCT05865002
- Testing
- AUR107
- Where
- 37 sites in India
- Volunteers
- 50 people
- Sponsor
- Aurigene Discovery Technologies Limited
Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-D101 CAR-T cells in patients with DLL3-positive Relapsed/Refractory primary small…
- Trial name
- NCT07246304
- Testing
- TC-D101 CAR-T
- Where
- China
- Volunteers
- 24 people
- Sponsor
- TCRCure Biopharma Ltd.
Small Cell Lung Cancer
JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of JK-1201I with Topotecan in patients with relapsed extensive stage small cell lung cancer (ES SCLC).
- Trial name
- NCT06581380
- Testing
- JK-1201I, Topotecan
- Volunteers
- 394 people
- Sponsor
- JenKem Technology Co., Ltd.
Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC
Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or…
- Conditions
- Small Cell Lung Cancer (SCLC), Relapsed/Refractory SCLC, Extensive-stage SCLC
- Trial name
- NCT07744256
- Testing
- EB-DART-NK01, Lymphodepleting chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
Small Cell Lung Cancer
A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer
This study was designed to compare the efficacy and safety of IBB0979 in combination with topotecan versus topotecan in subjects with relapsed small cell lung cancer (SCLC).
- Trial name
- NCT07076095
- Testing
- IBB0979, topotecan hydrochloride for injection
- Volunteers
- 200 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Non Small Cell Lung Cancer
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
This study is to determine if Healthy Donor FMT (hdFMT) improves the body's ability to fight cancer in patients with relapsed/refractory PD-L1 Positive NSCLC.
- Trial name
- NCT05669846
- Testing
- Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Diwakar Davar